Septerna (NASDAQ:SEPN) COO Sells $97,360.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $4,240,247.06. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Elizabeth Bhatt also recently made the following trade(s):

• On Wednesday, February 18th, Elizabeth Bhatt sold 4,000 shares of Septerna stock. The shares were sold at an average price of $28.97, for a total value of $115,880.00.

Septerna Stock Performance

Septerna stock opened at $26.13 on Monday. The company has a market capitalization of $1.17 billion, a P/E ratio of -23.54 and a beta of 3.50. Septerna, Inc. has a fifty-two week low of $5.73 and a fifty-two week high of $32.63. The stock has a 50-day simple moving average of $26.20 and a 200-day simple moving average of $25.18.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. As a group, analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Hedge Funds Weigh In On Septerna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new position in Septerna during the 4th quarter worth approximately $88,000. Seven Fleet Capital Management LP acquired a new position in Septerna during the 4th quarter worth approximately $319,000. XTX Topco Ltd acquired a new position in Septerna during the 4th quarter worth approximately $650,000. VARCOV Co. acquired a new position in Septerna during the 4th quarter worth approximately $631,000. Finally, Virtus Investment Advisers LLC acquired a new position in Septerna during the 4th quarter worth approximately $292,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on SEPN shares. Wells Fargo & Company boosted their price target on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. boosted their price target on Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Truist Financial boosted their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Finally, Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.14.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.